Three studies investigated the proportion of Tregs among CD4+ cells in patients that exhibit residual symptoms of COVID-19 and compared them to seronegative controls and individuals that recovered from COVID-19 (66–68) (Figure 3). This evidence concerns the gene CD4 and COVID-19.